ХИМЕНЕС АНТОН Ана Исабель (ES),ГОНСАЛЕС ФАХАРДО Виктория (ES),РУС ПАЛОМАР Вероника (ES)
申请号：
RU2015112121
公开号：
RU2015112121A
申请日:
2013.09.04
申请国别(地区):
RU
年份:
2016
代理人:
摘要：
1. Application in E RNA target sequence which is SEQ ID NO: 1, for preparing a medicament for the treatment of dry eye and / or ocular pain, wherein E RNA administered in a dose from about 0.1 mg to about 10 mg sutki.2. Use according to claim. 1 wherein E RNA administered in a dose from about 0.5 mg to about 1.5 mg sutki.3. Use according to claim. 1 wherein E RNA administered at a dose of about 0.6 mg or about 0.9 mg per eye sutki.4. Use according to claim 1, wherein said RNA-E is administered for 5-15 dney.5. Use according to claim. 4, wherein said E-RNA is administered for 10 dney.6. Use according to claim. 1 wherein said RNA is introduced in E postoyanno.7. . Use according to claim 1, wherein said RNA-E is a compound defined by the sequence SEQ ID NO: 2.8. Use according to claim. 1 wherein said E RNA glaz.9 administered topically. E RNA target sequence which is SEQ ID NO: 1, for use in the treatment of dry eye and / or ocular pain, wherein E RNA administered in a dose from about 0.1 mg to about 10 mg per sutki.10. A method for treating dry eye and / or ocular pain, wherein E RNA target sequence which is SEQ ID NO: 1, administered in a dose of from about 0.1 mg to about 10 mg per sutki.11. Medical kit for administering E RNA target sequence which is SEQ ID NO: 1 comprising the proposed E RNA target sequence which is SEQ ID NO: 1, wherein said dosage contains from about 0.1 mg to about 10 mg for daily administration and printed instructions for administering E RNA target sequence which is SEQ ID NO: 1, at pp. 1-7.1. Применение ми-РНК, мишенью которой является последовательность SEQ ID NO:1, для получения лекарственного средства для лечения сухих глаз и/или глазной боли, при этом ми-РНК вводят в дозе примерно от 0,1 мг до примерно 10 мг в сутки.2. Применение по п. 1, при котором ми-РНК вводят в дозе примерно от 0,5 мг до примерно 1,5 мг в сутки.3. Применение по п. 1, при котором ми-РНК вводят в дозе примерно 0,6 мг или примерно 0,9 мг на глаз в сутки.4. Применение п
